Altimmune Begins Multinational Phase 2 Clinical Trial of HepTcellTM, a Novel Immunotherapeutic for the Treatment of Chronic Hepatitis B

NEXT STORY
TRACON Pharmaceuticals Announces Acceptance of the Envafolimab (KN035) NDA by the NMPA in China that was Submitted by its Corporate Partners Alphamab Oncology and 3D Medicines
PREV STORY
Zai Lab Announces Upcoming Presentation at 39th Annual J.P. Morgan Healthcare Conference
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Sun BioPharma, Inc. Announces Data Presentation at the ASCO 2020 Annual Gastrointestinal Cancers Symposium

author_avatar
NASDAQ Market News

OSE Immunotherapeutics Presents Selective SIRP-alpha antibodies: OSE-172, a next-generation myeloid checkpoint inhibitor at the World Immunotherapy Congress

Basel, Oct. 29-31, 2018 NANTES, France, Oct. 30, 2018 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics ...

author_avatar
NASDAQ Market News

Vaxil Announces CEO Resignation

author_avatar
NASDAQ Market News